Alpha Teknova, Inc. (TKNO) AI Stock Analysis

Alpha Teknova, Inc. specializes in supplying essential reagents critical to the global life sciences sector, supporting the discovery, development, and production of biopharmaceuticals such as drug therapies, vaccines, and molecular diagnostics. Founded in 1996 and based in Hollister, California, the company's product portfolio includes pre-poured media plates for cell growth and cloning, liquid cell culture media for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. Alpha Teknova serves a broad client base that includes pharmaceutical and biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic franchises, and research institutions.

Revenue increased to $40.5M in FY2025, up 7.4% from $37.7M in FY2024, following a 5-year revenue CAGR of 5.3% from FY2020 to FY2025. Gross margin improved to 33.2% in FY2025 from 19.2% in FY2024, though it remained lower than the 47.8% recorded in FY2021. Operating margin stood at -41.9% in FY2025, recovering from -69.3% in FY2024 and -119.9% in FY2022. Net loss narrowed to -$17.3M in FY2025 compared to -$26.7M in FY2024 and -$47.5M in FY2022, resulting in an EPS of -$0.33. Over the trailing twelve months, revenue reached $43.7M with quarterly revenue growing 18.5% year-over-year for the period ending June 30, 2026, while trailing twelve-month profit margin was -38.4%.

As of June 30, 2026, Alpha Teknova held $17.4M in cash and short-term investments against total debt of $27.4M, resulting in net debt of $10.0M. The company had shareholders' equity of $62.6M and total assets of $95.9M, yielding a debt-to-equity ratio of 0.44 and a current ratio of 4.49. In FY2025, operating cash flow was -$8.6M and free cash flow was -$9.8M. Capital expenditures totaled $1.1M in FY2025, while share issuance brought in $55,000, and share count expanded 91.5% over a 5-year span.

With a market cap of $380.1M and an enterprise value of $489.4M, Alpha Teknova trades at a price-to-sales multiple of 8.7x and an EV-to-revenue multiple of 11.2x. Its price-to-sales multiple sits above the 4.1x median of its US-listed Healthcare peers. The company's price-to-book ratio is 7.7x. Over the past year, TKNO shares gained 34.6%, outperforming the S&P 500 (SPY) return of 16.8%. Over a 5-year period, however, TKNO generated a return of -69.4% compared to an 83.0% gain for the benchmark.

Wall Street analyst coverage shows 7 Strong Buy ratings and 1 Hold rating, with no Buy, Sell, or Strong Sell ratings. The mean price target is $9.67, representing a 36.5% premium to the last close of $7.08. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $46.0M and an EPS of -$0.24. For the next fiscal year, projected revenue is $52.7M, representing 14.5% revenue growth, alongside an EPS estimate of -$0.19. The company beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Alpha Teknova, Inc. (TKNO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TKNO income statement, TKNO balance sheet, TKNO key metrics, TKNO analyst forecast, TKNO chart. See the TKNO stock overview for the latest quote and news.